What evidence gaps are holding back CAR-T therapies for solid tumors?

Why can't CAR-T cells get deep enough into solid tumors?

The first major evidence gap is that we don't have a clear, quantitative picture of how CAR-T cells move through and penetrate solid tumors. A 2022 multimodal imaging study tracked CAR-T cells in mice from whole-body down to single-cell level and found that most CAR-T cells accumulate at the tumor periphery and around blood vessels, not deep inside the tumor mass [2]. This means even when cells reach the tumor site, they often fail to infiltrate the core where many cancer cells reside. The same study showed that local IL-2 injections initially boosted CAR-T cell proliferation, but long-term overstimulation actually halted the added therapeutic effect—revealing a critical gap in our understanding of how to sustain infiltration without causing exhaustion [2].

Regional delivery of CAR-T cells directly into the tumor site has been shown to be safe and feasible, promoting infiltration and proliferation, and even igniting systemic immunity [9]. However, this approach still faces the challenge that once inside, CAR-T cells encounter a hostile microenvironment that suppresses their function. The evidence gap here is mechanistic: we need to understand the precise signals that guide CAR-T cell trafficking from the periphery into the tumor core, and how to maintain their activity once they arrive.

How do you hit a moving target when every tumor cell looks different?

Solid tumors are notoriously heterogeneous—different cells within the same tumor can express different surface antigens, and tumors often evolve to lose the very antigen the CAR-T cells are designed to recognize. This 'antigen escape' is a major evidence gap because we lack reliable biomarkers to predict which antigens will be stable targets [3][6]. A 2023 study with 214 citations introduced a clever workaround: probiotic-guided CAR-T cells (ProCARs), where engineered bacteria colonize the tumor and release synthetic targets that label the tumor tissue for CAR-mediated lysis, bypassing the need for a single tumor-specific antigen [7]. This approach showed safety and efficacy in multiple mouse models, but it has not yet been tested in humans, so the evidence gap remains about whether it will work in real patients with complex immune systems.

Another strategy is logic-gated CAR-T cells that require two antigens to be present before activating, which could reduce off-tumor toxicity [3]. But the evidence base for these designs is still preclinical. The largest clinical trials for solid tumors have targeted GD2 (in neuroblastoma) and HER2, with early results described as 'encouraging' but needing validation on a larger scale [8]. The gap is clear: we don't have enough high-quality clinical data to know which multi-antigen targeting strategies are safe and effective in humans.

Why do CAR-T cells burn out so fast in solid tumors?

Even when CAR-T cells reach the tumor and recognize their target, they often become dysfunctional or exhausted within days to weeks. The immunosuppressive tumor microenvironment (TME) is a key culprit—it contains factors that actively suppress T cell activity, including regulatory T cells, myeloid-derived suppressor cells, and inhibitory cytokines [1][4]. A 2024 study found that genetically disrupting SUV39H1, a gene that promotes heterochromatin formation, reprogrammed CAR-T cells into self-renewing, stem-like populations with decreased expression of dysfunction genes, leading to potent and durable functional persistence against multiple tumor rechallenges in mice [5]. This suggests that epigenetic reprogramming could close the persistence gap, but the evidence is still limited to animal models.

Combination therapies with immune checkpoint inhibitors are being explored to counteract TME suppression, and early clinical trials are underway [10]. However, a 2024 review noted that 'most research is in development' and that even promising results from GD2- and HER2-CAR-T trials 'must be reproduced and validated on a larger scale' [8]. The evidence gap here is twofold: we don't fully understand the molecular pathways that drive CAR-T exhaustion in solid tumors, and we lack robust clinical data on which combination strategies (e.g., with checkpoint inhibitors, targeted inhibitors, or cytokines) are most effective and safe.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2022 to 2025, 5 from 2024 or later, 9 in Q1 journals, collectively cited 670 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 44 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions